Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Matthew Gagne,Barbara J Flynn,Christopher Cole Honeycutt,Dillon R Flebbe,Shayne F Andrew,Samantha J Provost,Lauren McCormick,Alex Van Ry,Elizabeth McCarthy,John-Paul M Todd,Saran Bao,I-Ting Teng,Shir Marciano,Yinon Rudich,Chunlin Li,Shilpi Jain,Bushra Wali,Laurent Pessaint,Alan Dodson,Anthony Cook,Mark G Lewis,Hanne Andersen,Jiří Zahradník,Mehul S Suthar,Martha C Nason,Kathryn E Foulds,Peter D Kwong,Mario Roederer,Gideon Schreiber,Robert A Seder,Daniel C Douek

DOI: https://doi.org/10.1038/s41467-024-51046-w

2024-08-12

Abstract:SARS-CoV-2 has the capacity to evolve mutations that escape vaccine- and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the virus would thus be a valuable biomedical tool that would maintain its efficacy despite the ongoing emergence of new variants. Here, we challenge male rhesus macaques with SARS-CoV-2 Delta-the most pathogenic variant in a highly susceptible animal model. At the time of challenge, we also treat the macaques with aerosolized RBD-62, a protein developed through multiple rounds of in vitro evolution of SARS-CoV-2 RBD to acquire 1000-fold enhanced ACE2 binding affinity. RBD-62 treatment equivalently suppresses virus replication in both upper and lower airways, a phenomenon not previously observed with clinically approved vaccines. Importantly, RBD-62 does not block the development of virus-specific T- and B-cell responses and does not elicit anti-drug immunity. These data provide proof-of-concept that RBD-62 can prevent severe disease from a highly virulent variant.